Astrazeneca (AZN) Free Cash Flow (2009 - 2026)
Astrazeneca (AZN) posted quarterly Free Cash Flow of -$1.9 billion for Q2 2026, down 22.41% year-over-year from -$2.4 billion in Q2 2025, and down 439.49% quarter-over-quarter from $547.0 million in Q1 2026.
Astrazeneca (AZN) Free Cash Flow (2009 - 2026) Analysis & Trends
Astrazeneca's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$1.9 billion for Q2 2026.
- In Q2 2026, Free Cash Flow fell 22.41% year-over-year to -$1.9 billion; the TTM figure through Jun 2026 stood at -$3.0 billion (up 20.44% YoY), while the FY2025 annual figure was $15.9 billion, up 13.76% from the prior year.
- Free Cash Flow for Q2 2026 stood at -$1.9 billion, down from $547.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $2.9 billion in Q3 2025, with the low at -$4.6 billion in Q4 2025.
- The 5-year median for Free Cash Flow is $261.5 million (2022), against an average of -$361.1 million.
- Peak annual rise in Free Cash Flow reached 586.33% in 2025, while the deepest fall reached 497.12% in 2025.
- Astrazeneca's Free Cash Flow stood at $253.0 million in 2022, then increased by 6.72% to $270.0 million in 2023, then tumbled by 1262.96% to -$3.1 billion in 2024, then sank by 45.99% to -$4.6 billion in 2025, then surged by 59.49% to -$1.9 billion in 2026.
- Business Quant data shows AZN's Free Cash Flow at -$1.9 billion in Q2 2026, $547.0 million in Q1 2026, and -$4.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.86 Bn |
| Jun 30, 2026 | -1.86 Bn |
| Mar 31, 2026 | 547.00 Mn |
| Mar 31, 2026 | 547.00 Mn |
| Dec 31, 2025 | -4.58 Bn |
| Dec 31, 2025 | -4.58 Bn |
| Sep 30, 2025 | 2.86 Bn |
| Sep 30, 2025 | 2.86 Bn |
| Jun 30, 2025 | -1.52 Bn |
| Jun 30, 2025 | -1.52 Bn |
| Mar 31, 2025 | 429.00 Mn |
| Mar 31, 2025 | 429.00 Mn |
| Dec 31, 2024 | -3.14 Bn |
| Dec 31, 2024 | -3.14 Bn |
| Sep 30, 2024 | 417.00 Mn |
| Sep 30, 2024 | 417.00 Mn |
| Jun 30, 2024 | 382.00 Mn |
| Jun 30, 2024 | 382.00 Mn |
| Mar 31, 2024 | 417.00 Mn |
| Mar 31, 2024 | 417.00 Mn |